Arcutis Biotherapeutics, Inc. - Common stock · Transaction May 29, 2026 · Filed Jun 8, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · ARQT
-0.51% · -$0.1300 · Vol 1.8M
Market closed · last close 4:00 PM ET · price as of 17:07:08 ET
Arcutis Biotherapeutics Inc
Biotechnology
$25.16
Follow $ARQT
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ARQT by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredMon Oct 5 · market closed · Markets closed · resumes Mon 9:30 ET · ARQT
MethodologyARQT
Arcutis Biotherapeutics Inc
Mon Oct 5 · market closed · Markets closed · resumes Mon 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
55/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Mon Oct 5 · market closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is ARQT moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Arcutis Biotherapeutics Inc
PHARMACEUTICAL PREPARATIONSListed since
2020
Employees
354
Country
US
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$25.64
Day high
$25.78
Day low
$25.01
Previous close
$25.29
52W high
$31.20
-19.36% from high
52W low
$19.50
48% of range
Market cap
$3.2B
P/E
110.89×
EPS
$-0.0500
Beta
0.34
Shares out
125.7M
Volume
1.8M
0.62× rel vol
Avg volume
2.9M
VWAP
$25.22
Price history computed in-house
1W
-7.94%
1M
+5.27%
3M
-9.07%
1Y
+26.31%
YTD
-13.36%
SMA 50 $25.69 · below
SMA 200 $25.21 · below
52W position 48%
ARQT overview
Related filings and maps
Public disclosures
Congress activity in ARQT
Official filing ↗
Arcutis Biotherapeutics, Inc. - Common stock · Transaction Mar 3, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
Arcutis Biotherapeutics, Inc. - Common stock · Transaction Dec 11, 2025 · Filed Jan 12, 2026 · $1,001 to $15,000
Arcutis Biotherapeutics, Inc. - Common stock · Transaction Sep 15, 2023 · Filed Oct 15, 2023 · $1,001 to $15,000
Arcutis Biotherapeutics, Inc. - Common stock · Transaction Apr 17, 2023 · Filed May 19, 2023 · $1,001 to $15,000
Federal contracts
ARQT contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ARQT in this window.
Lobbying spend
ARQT lobbying filings, year to date.
Registered lobbying filings matched to Arcutis Biotherapeutics Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ARQT in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for ARQT.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.